ORGS (Orgenesis) EPS (Basic) : $-24.53 (TTM As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Orgenesis EPS (Basic)?

Orgenesis's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-1.93. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-24.53.

Orgenesis's EPS (Diluted) for the three months ended in Sep. 2024 was $-1.93. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-24.53.

Orgenesis's EPS without NRI for the three months ended in Sep. 2024 was $-1.85. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -31.22.

During the past 3 years, the average EPS without NRI Growth Rate was 27.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Orgenesis's highest 3-Year average EPS without NRI Growth Rate was 27.00% per year. The lowest was -582.00% per year. And the median was 1.25% per year.

Orgenesis EPS (Basic) Historical Data

The historical data trend for Orgenesis's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis EPS (Basic) Chart

Orgenesis Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-17.70

2.90

-7.40

-5.90

-19.10

Orgenesis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.12	-17.40	-2.90	-2.30	-1.93

Orgenesis EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Orgenesis's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-55.361	-	0)	/	2.901
	=	-19.08

Orgenesis's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-9.12	-	0)	/	4.715
	=	-1.93

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.53

Orgenesis (OTCPK:ORGS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Orgenesis EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Orgenesis's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (OTCPK:ORGS) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

45O0:Germany

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.

Executives

Jacob Safier	10 percent owner	C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Elliot Maltz	officer: Chief Financial Officer	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Efrat Assa Kunik	officer: Chief Development Officer	C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips	director	C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber	officer: Chief Scientific Officer	17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin	director	7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler	director	4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan	officer: CEO	20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles	10 percent owner	AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger	10 percent owner	DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret	officer: See Remarks	48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda	director	2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452